Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Surg Case Rep ; 7(1): 42, 2021 Feb 06.
Article in English | MEDLINE | ID: mdl-33547982

ABSTRACT

BACKGROUND: Skeletal muscle metastasis from gastric cancer is rare and has a poor prognosis. We reported a case of gluteal muscle metastasis with peritoneal dissemination from gastric cancer during postoperative adjuvant chemotherapy. CASE PRESENTATION: A 64-year-old man with gastric cancer underwent distal gastrectomy with D2 lymph node resection. The pathological diagnosis was poorly differentiated adenocarcinoma and signet cell carcinoma, T3N3bM0, Stage IIIC. Metastases were found in all regional lymph nodes, except 11p. The resection margin was negative. S-1 plus docetaxel therapy was administered as postoperative adjuvant chemotherapy. Six month post-operation, the patient presented with right gluteal muscle tenderness and abdominal distension. Computed tomography revealed a solid mass in the right gluteal muscle, a disseminated nodule on the abdominal wall, and massive ascites. Pathological examination of the gluteal muscle revealed signet cell carcinoma, similar to the resected gastric cancer. The tumor was diagnosed as gastric cancer metastases. Ascites cytology was class V. Thereafter, the patient underwent one course of capecitabine plus cisplatin combined with trastuzumab. Radiation therapy was also administered to relieve the pain of gluteal muscle metastasis. However, chemoradiotherapy was ineffective, and the patient died 2 months after the recurrence. CONCLUSIONS: Skeletal muscle metastasis and peritoneal dissemination during adjuvant chemotherapy indicated a poor prognosis.

2.
Gan To Kagaku Ryoho ; 47(6): 989-992, 2020 Jun.
Article in Japanese | MEDLINE | ID: mdl-32541181

ABSTRACT

A 61-year-old man underwent CapeOX plus bevacizumab chemotherapyafter right hemicolectomyfor metastatic ascending colon cancer. On the 7th dayafter the first administration, he had sudden abdominal pain and nausea. Contrast-enhanced computed tomographyrevealed aortic thrombosis and a superior mesenteric artery(SMA)embolism that was considered to be associated with bevacizumab. Bevacizumab was discontinued and anticoagulation therapyusing heparin and urokinase was performed. Brain infarction of the left middle cerebral arteryoccurred on the 15th dayafter the first administration and thrombectomywas performed. Anticoagulation therapyusing heparin, bayaspirin, and edoxaban tosilate hydrate was performed. The aortic thrombosis and SMA embolism resolved with treatment, but the patient died following an increase in peritoneal dissemination. It should be noted that unexpectedlysevere aortic thrombosis occurred during the first administration of CapeOX plus bevacizumab for metastatic colon cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colonic Neoplasms , Thrombosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab , Capecitabine , Colonic Neoplasms/drug therapy , Humans , Male , Middle Aged , Organoplatinum Compounds , Oxaliplatin , Thrombosis/chemically induced
3.
Surg Today ; 44(11): 2077-85, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24473667

ABSTRACT

PURPOSE: To evaluate the anatomical variations in the middle hepatic vein tributaries (V5/V8) for determining the reconstruction strategy in right lobe living donor liver transplantation (LDLT). METHODS: The V5/V8 variations were examined in 268 patients and were classified into three and two types, respectively. The reconstruction rate (RR), patency rate (PR) and clinical outcomes were retrospectively evaluated in 46 right lobe LDLT cases. RESULTS: In terms of V5 variations, the RR and PR were significantly higher for type 2 than type 3 (82.6 vs. 44.4 % and 73.7 vs. 25.0 %, respectively). The alanine aminotransferase level on postoperative day (POD) 5 in the V5 patent group was significantly lower than in the occluded group (123 vs. 191 IU/dL). Regarding V8 variations, the RR and PR were significantly higher for type 1 than type 2 (44.4 vs. 17.6 % and 75.0 vs. 33.3 %, respectively). The aspartate aminotransferase level on POD 3 was significantly lower in the V8 patent group than in the occluded group (50 vs. 121 IU/dL). CONCLUSION: For right lobe grafts with single large V5 (type 2) or V8 (type 1) variations, reconstruction is necessary. Our new classification of the MHV tributaries is useful for determining the reconstruction strategy to use in right lobe LDLT.


Subject(s)
Hepatic Veins/anatomy & histology , Hepatic Veins/diagnostic imaging , Imaging, Three-Dimensional/methods , Tomography, X-Ray Computed/methods , Adult , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Biomarkers/blood , Female , Humans , Liver Transplantation , Living Donors , Male , Middle Aged , Plastic Surgery Procedures , Retrospective Studies , Young Adult
4.
Fukuoka Igaku Zasshi ; 104(12): 599-602, 2013 Dec.
Article in Japanese | MEDLINE | ID: mdl-24693692

ABSTRACT

Incarcerated diaphragmatic hernia after laparoscopic right hepatectomy is very rare. An 81-year-old man underwent laparoscopic right hepatectomy for giant hepatic hemangioma. Twenty months after the surgery, he began to complain of nausea and abdominal pain and was brought to our hospital. Chest X-ray showed an abdominal gas shadow above the right diaphragm and computed tomography showed herniation of the colon into the right thoracic cavity. We diagnosed ileus due to incarcerated diaphragmatic hernia and performed emergency operation under laparoscopic surgery. After successfully reducing the prolapsed colon back to the abdominal cavity, the diaphragmatic hernia orifice was repaired. Incarcerated diaphragmatic hernia sometimes causes the fatal state. Clinicians must therefore consider such findings a late complication of laparoscopic hepatectomy.


Subject(s)
Hemangioma/surgery , Hepatectomy , Hernia, Diaphragmatic/surgery , Herniorrhaphy , Laparoscopy , Liver Neoplasms/surgery , Postoperative Complications/surgery , Aged, 80 and over , Emergencies , Hernia, Diaphragmatic/complications , Hernia, Diaphragmatic/diagnosis , Humans , Ileus/etiology , Ileus/surgery , Male , Postoperative Complications/diagnosis , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
5.
Microbiol Immunol ; 55(9): 645-56, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21699557

ABSTRACT

CD30 ligand (CD30L, CD153) is a type II membrane-associated glycoprotein belonging to the tumor necrosis factor family. It is shown here that CD30L knock out (KO) mice are highly susceptible to primary infection with Listeria monocytogenes as assessed by the survival rate. There were significantly more bacteria on day 3 after infection in the peritoneal cavity, spleen and liver of CD30LKO mice than in wild type (WT) mice. The innate function of memory phenotype (MP) CD44+ CD4+ T cells for interferon-gamma production was significantly lower in CD30LKO mice than in WT mice in response to interleukin (IL)-12 and IL-15 in vitro. Depletion of CD4+ T cells by in vivo administration of anti-CD4 mAb at an early stage after infection hampered protection against Listeria. Furthermore, in vivo administration of agonistic anti-CD30 mAb restored protection against Listeria in CD30LKO mice, whereas treatment with soluble mCD30-Ig hampered protection in WT mice. Taken together, it appears that CD30L/CD30 signaling plays an important role in innate MPCD4+ T cell-mediated protection against infection with L. monocytogenes.


Subject(s)
CD30 Ligand/immunology , CD4-Positive T-Lymphocytes/immunology , Immunologic Memory , Listeria monocytogenes/immunology , Listeriosis/immunology , Animals , Bacterial Load , CD30 Ligand/deficiency , CD4-Positive T-Lymphocytes/chemistry , Disease Models, Animal , Hyaluronan Receptors/analysis , Interleukin-12/immunology , Interleukin-15/immunology , Liver/microbiology , Lymphocyte Depletion , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Peritoneal Cavity/microbiology , Spleen/microbiology , Survival Analysis , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/immunology
6.
Liver Int ; 31(4): 474-84, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21199296

ABSTRACT

BACKGROUND AND AIMS: MicroRNAs are small non-coding RNA molecules that post-transcriptionally regulate gene expression. Liver-specific microRNA-122 (miR-122) has been shown to facilitate the replication of hepatitis C virus (HCV) in human hepatoma cells in vitro. However, the clinical significance of hepatic miR-122 on HCV in human body is unclear. METHODS: Hepatic miR-122 expression was quantified using quantitative reverse-transcription polymerase chain reaction. We investigated the correlation between miR-122 expression and HCV load in liver samples from 185 patients seropositive for HCV antibody, including 151 patients seropositive for HCV RNA, and 31 patients seronegative for HCV RNA. RESULTS: Although hepatic miR-122 expression was weakly and positively correlated with the serum HCV load (ρ=0.19, P<0.05), it was not correlated with the hepatic HCV load (ρ=-0.14, P=0.08). The absence of a correlation between miR-122 expression and hepatic HCV load was also confirmed after stratification of histopathological liver damage (inflammatory activity grades and fibrosis stages). Furthermore, hepatic miR-122 expression in patients seronegative for HCV RNA was significantly higher than that in patients seropositive for HCV RNA (P<0.0001). The level of hepatic miR-122 expression was inversely correlated with the severity of functional and histopathological liver damage (P<0.0001), serum transaminase levels (P<0.0005). CONCLUSIONS: Compared with in vitro findings, hepatic miR-122 expression is not correlated with HCV load in the human liver. Therefore, miR-122, by itself, is not a critical molecular target for HCV therapy. MiR-122 expression is inversely correlated with both functional and histopathological liver damage.


Subject(s)
Hepatitis C/metabolism , Liver/metabolism , MicroRNAs/metabolism , Aged , Female , Hepatitis Antibodies/blood , Hepatitis C/genetics , Humans , Japan , Liver/pathology , Male , Middle Aged , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction , Statistics, Nonparametric , Viral Load
7.
Ann Surg Oncol ; 18(4): 1204-11, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21076943

ABSTRACT

BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). METHODS: Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. RESULTS: ERCC1 expression was observed in 33% of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33% of the nuclei were stained; ERCC1 low expression group (n = 44): 33% or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). CONCLUSIONS: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/metabolism , Cisplatin/therapeutic use , DNA-Binding Proteins/metabolism , Drug Resistance, Neoplasm , Endonucleases/metabolism , Blotting, Western , Carcinoma, Hepatocellular/pathology , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/genetics , Endonucleases/antagonists & inhibitors , Endonucleases/genetics , Female , Humans , Immunoenzyme Techniques , Liver Neoplasms/drug therapy , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Middle Aged , RNA, Small Interfering/genetics , Survival Rate , Treatment Outcome , Tumor Cells, Cultured
8.
Surg Today ; 40(10): 982-5, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20872205

ABSTRACT

Cholestatic hepatitis is a life-threatening recurrent pattern of hepatitis C virus (HCV) in immunosuppressed patients, for which curative treatment has not yet been established. We report the successful treatment of cholestatic hepatitis in a 59-year-old man who had undergone right lobe living donor liver transplantation (LDLT) for liver cirrhosis (LC) caused by HCV. Following uneventful surgery and an uncomplicated posttransplant clinical course, there was an abrupt increase in total bilirubin in comparison to aminotransferase on postoperative day (POD) 60 (total bilirubin 16.2 mg/dl, alanine aminotransferase 100 U/l, HCV-RNA 390 kIU/ml). The histological findings of the liver tissue showed lymphocyte infiltration in the periportal zone and severe cholestasis. Considering the clinical course, cholestatic hepatitis was strongly suspected and pegylated interferon and ribavirin therapy was started immediately, resulting in not only a viral response, but minimal progression of fibrosis. This case serves to demonstrate that early diagnosis and timely initiation of optimal antiviral therapy is essential for the resolution of cholestatic hepatitis C.


Subject(s)
Antiviral Agents/therapeutic use , Cholestasis, Intrahepatic/diagnosis , Early Diagnosis , Hepatitis C, Chronic/diagnosis , Liver Transplantation/adverse effects , Living Donors , Biopsy , Cholangiography , Cholestasis, Intrahepatic/etiology , Cholestasis, Intrahepatic/therapy , Diagnosis, Differential , Drug Carriers , Follow-Up Studies , Hepacivirus/genetics , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/therapy , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Liver Cirrhosis , Liver Neoplasms/surgery , Male , Middle Aged , Polyethylene Glycols/therapeutic use , Postoperative Complications , RNA, Viral/analysis , Recombinant Proteins , Ribavirin/therapeutic use , Ultrasonography, Doppler
9.
J Gastroenterol Hepatol ; 25(5): 978-84, 2010 May.
Article in English | MEDLINE | ID: mdl-20546453

ABSTRACT

BACKGROUND AND AIMS: The importance of hyponatremia in deceased donor liver transplantation (DDLT) has been recently discussed frequently. However, its impact on the outcomes in living donor liver transplantation (LDLT) has not yet been elucidated. The current study was designed to demonstrate the impact of pre-transplant sodium concentration on postoperative clinical outcomes. METHODS: One hundred and thirty-four patients who underwent LDLT for end-stage liver diseases were examined to evaluate the significance of pre-transplant hyponatremia (Na < or = 130 mEq/L) on the short-term clinical outcomes and the efficacy of the Model for End-Stage Liver Disease and serum sodium (MELD-Na) score using the sodium concentration and original MELD score. RESULTS: The preoperative sodium and MELD score for all patients were 133.9 mEq/L (range: 109-142) and 16.2 (range: 6-38), respectively. According to a multivariate analysis, not only the MELD score (P = 0.030) but also the sodium concentration (P = 0.005) were found to be significant predictive factors for short-term graft survival. Preoperative hyponatremia was a significant risk factor for the occurrence of sepsis (P < 0.001), renal dysfunction (P < 0.001) and encephalopathy (P = 0.026). The MELD-Na score was 19.6 (range: 6-51) and the area under the receiver-operator curve of that (c-statistics: 0.867) was higher than MELD score and sodium concentration (c-statistics: 0.820 and 0.842, respectively). CONCLUSION: Preoperative hyponatremia was a significant risk for postoperative complications and short-term graft loss. The addition of sodium concentration to MELD score might therefore be an effective predictor for post-transplant short-term mortality in LDLT.


Subject(s)
Hyponatremia/complications , Liver Diseases/surgery , Liver Transplantation , Living Donors , Sodium/blood , Adult , Aged , Biomarkers/blood , Female , Graft Rejection/blood , Graft Rejection/etiology , Graft Survival , Hepatic Encephalopathy/blood , Hepatic Encephalopathy/etiology , Humans , Hyponatremia/blood , Japan , Kaplan-Meier Estimate , Kidney Diseases/blood , Kidney Diseases/etiology , Liver Diseases/blood , Liver Diseases/complications , Liver Transplantation/adverse effects , Logistic Models , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Sepsis/blood , Sepsis/etiology , Time Factors , Treatment Outcome , Young Adult
11.
J Surg Oncol ; 100(7): 575-9, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19697358

ABSTRACT

BACKGROUND AND OBJECTIVES: Fascin is an actin-bundling protein and induces membrane protrusions and cell motility after the formation of lamellipodia or filopodia. Fascin expression has been reported to be associated with progression or prognosis in various neoplasms, but the role of fascin in hepatocellular carcinoma (HCC) remains unknown. The aim of this study was to investigate the clinicopathological and prognostic relevance of fascin by immunohistochemistry. METHODS: A total of 137 patients with HCC were stained with anti-fascin antibody. The tumor cells having unequivocal cytoplasmic and/or membranous fascin immunoreactivity were defined as fascin-positive. RESULTS: Immunohistochemically, 23 (16.8%) HCCs having unequivocal fascin immunoreactivity were found. Tumors showing fascin expression were larger and less differentiated than those showing no fascin expression (P = 0.0239 and 0.0018, respectively). Portal venous invasion, bile duct invasion, and intrahepatic metastasis were detected significantly more frequently in fascin-positive group (P = 0.0029, 0.0333, and 0.0403, respectively). In addition, high alpha-fetoprotein (AFP) levels were significantly associated with the fascin expression in HCC (P = 0.0116). Fascin-positive group had significantly poorer outcomes than fascin-negative group and was an independent prognostic factor for disease-free survival. CONCLUSIONS: Fascin might become a novel marker of progression in HCC and a significant indicator of a poor prognosis for patients with HCC.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/mortality , Carrier Proteins/metabolism , Liver Neoplasms/metabolism , Liver Neoplasms/mortality , Microfilament Proteins/metabolism , Aged , Aspartate Aminotransferases/analysis , Bile Ducts/pathology , Biomarkers, Tumor/metabolism , Blood Loss, Surgical , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Disease Progression , Disease-Free Survival , Female , Humans , Immunohistochemistry , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Middle Aged , Neoplasm Invasiveness , Portal Vein/pathology , Prognosis , alpha-Fetoproteins
12.
Chem Commun (Camb) ; (32): 4874-6, 2009 Aug 28.
Article in English | MEDLINE | ID: mdl-19652810

ABSTRACT

Pillar[5]arene from modified phenylethynyl groups was prepared; since the repeating pi-conjugated units were largely pi-delocalized via the through-space within the cavity, it showed temperature- and solvent-responsive blue-green emission.

13.
Transpl Int ; 22(8): 837-44, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19386077

ABSTRACT

The clinical importance of congestion of the remnant right lobe has not yet been fully elucidated in donors who donate their left lobe with the middle hepatic vein. The impact of congestion on clinical course and liver regeneration in 52 donor remnant livers were evaluated. The donors were divided into three groups according to the degree of the congestion: the mild [congestion ratio (CR) < 10%], moderate (CR ranged from 10% to 25%) and severe congestion groups (CR > 25%). The regeneration ratio of the graft at postoperative day 7 (7 POD) was 22.0 +/- 14.3% and inversely correlated with the CR in the remnant right lobe (P = 0.003). Aspartate aminotransferase and alanine aminotransferase at 7 POD were significantly higher in the severe CR group in comparison to the mild CR group (P = 0.003 and 0.019, respectively), but those of the three groups were comparable at 30 POD. The hospital stays were significantly longer in the severe CR group (P = 0.010). In conclusion, the congestion of the donors' remnant right liver can lead the transient liver dysfunction and poor regeneration. Therefore, the conversion of the graft from the left to right lobe might be appropriate according to the degree of the congestion.


Subject(s)
Hepatic Veins/transplantation , Liver Transplantation/adverse effects , Liver/blood supply , Living Donors , Adult , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Bilirubin/blood , Female , Humans , Length of Stay , Liver/surgery , Liver Circulation , Liver Regeneration , Male , Middle Aged , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...